Want to see RFL full AI Analyst Report?
RFL Stock Chart & Stats
$1.22
-$0.03(-1.52%)
At close: 4:00 PM EST
$1.22
-$0.03(-1.52%)
Day’s Range― - ―
52-Week Range$1.12 - $3.96
Previous CloseN/A
Volume21.81K
Average Volume (3M)81.34K
Market Cap
$163.84M
Enterprise Value$66.77M
Total Cash (Recent Filing)$30.50M
Total Debt (Recent Filing)$610.00K
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding51,212,833
10 Day Avg. Volume101,467
30 Day Avg. Volume81,339
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.53
Price to Sales (P/S)54.22
P/FCF Ratio-2.63
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue68.13
Enterprise Value/Gross Profit85.93
Enterprise Value/Ebitda-2.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt and a sizable equity cushion provide durable financial flexibility to fund clinical programs, pursue licensing or commercialization, and withstand near-term cash burn without immediate solvency risk. This structural strength supports strategic optionality over several quarters.
Phase 3 Completion And FDA EngagementCompletion of the pivotal Phase 3 and formal FDA interactions materially reduce clinical and regulatory binary risk, positioning the company to transition toward commercialization. This structural progress can enable future revenue, partnering, or licensing opportunities over the medium term.
Exclusive MIT License Expands Alzheimer’s IPAcquiring exclusive IP for an ApoE4-targeted cyclodextrin use broadens the company’s patent estate and addresses a large, differentiated Alzheimer’s subpopulation. This durable intellectual-property extension strengthens moat and long-term upside beyond the rare-disease program.
Bears Say
Sustained Negative Operating Cash FlowConsistent ~-$32M operating and free cash flow indicates structural cash burn that will require financing, asset monetization, or sustained capital support. Over multiple quarters this weak cash generation constrains reinvestment and increases dilution or funding risk for commercialization.
Very Small And Declining Revenue With Large LossesSub-$1M revenue versus ~$32M losses shows the business lacks sustainable operating income. Persistent negative margins and declining sales create a structural gap between R&D/commercial ambitions and the company’s ability to self-fund growth without significant external capital or transformative revenue events.
Eroding Equity And Negative Returns (ROE)Declining equity and ~-39% ROE indicate the company’s operations are eroding shareholder value over time. This structural deterioration can limit strategic options, undermine investor confidence for future financings, and signal recurring losses that may persist absent successful commercialization or licensing.
Rafael Holdings News
RFL FAQ
What was Rafael Holdings Inc’s price range in the past 12 months?
Rafael Holdings Inc lowest stock price was $1.12 and its highest was $3.96 in the past 12 months.
What is Rafael Holdings Inc’s market cap?
Rafael Holdings Inc’s market cap is $163.84M.
When is Rafael Holdings Inc’s upcoming earnings report date?
Rafael Holdings Inc’s upcoming earnings report date is Nov 02, 2026 which is in 119 days.
How were Rafael Holdings Inc’s earnings last quarter?
Rafael Holdings Inc released its earnings results on Jun 11, 2026. The company reported -$0.082 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.082.
Is Rafael Holdings Inc overvalued?
According to Wall Street analysts Rafael Holdings Inc’s price is currently Overvalued.
Does Rafael Holdings Inc pay dividends?
Rafael Holdings Inc pays a Semiannually dividend of $0.02 which represents an annual dividend yield of N/A. See more information on Rafael Holdings Inc dividends here
What is Rafael Holdings Inc’s EPS estimate?
Rafael Holdings Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rafael Holdings Inc have?
Rafael Holdings Inc has 51,212,833 shares outstanding.
What happened to Rafael Holdings Inc’s price movement after its last earnings report?
Rafael Holdings Inc reported an EPS of -$0.082 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 19.101%.
Which hedge fund is a major shareholder of Rafael Holdings Inc?
Currently, no hedge funds are holding shares in RFL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rafael Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.51%
12-Months-Change
Fundamentals
Return on Equity
-38.97%
Trailing 12-Months
Asset Growth
-14.90%
Trailing 12-Months
Company Description
Rafael Holdings Inc
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Technical Analysis
JW Mays
―
New England Realty Associates Partnershi
―
Fathom Holdings
―
Offerpad Solutions
―
Star Holdings
―
Ownership Overview
30.68% Insiders
3.46% Mutual Funds
0.26% Other Institutional Investors
62.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---